New Prostate Cancer Biomarker May Have Been Detected in Study of Genetic Data Translation

New Prostate Cancer Biomarker May Have Been Detected in Study of Genetic Data Translation
Researchers working on new methods to translate genetic data into possible novel and targeted treatments for prostate cancer may have found a new pathway — and biomarker — indicative of this type of cancer, according to a study, titled "Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer," published in the journal PLOS ONE. Prostate cancer is the second most diagnosed cancer among American men, with an estimated 220,000 or more new cases in 2015. The cancer tends to have multiple tumor sites within a patient's prostate and each can be genetically different. "With the availability of patient genomic data, we can look deep inside a tumor to consider its genetic background and find more effective prostate cancer treatments," Jennifer S. Myers, a graduate student in the Department of Chemistry and Biochemistry at Florida State University, said in a news release. The expansion of genomic and proteomic technology and methodology has improved the characterization of tumor biology, driving the search for more accurate cancer biomarkers. Gene and protein expression differences between normal and malignant prostate tissues serve as a pool for putative diagnostic, prognostic, and risk stratification biomarkers. However, scientists are challenged in pinpointing amid the data of over 20,000 genes the exact genetic changes that matter in cancer development, progression, and treatment. Dr. Myers and her
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *